Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Inclusion Criteria: 1. Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart; 2. A definite diagnosis of B-cell Lymphocyte Leukemia, which meets any of the following criteria: Relapsed : a) relapsed within 12 months after first remission;Refractory: a) no remission after six weeks of induction therapy or no remission after two courses of induction therapy; b) relapsedafter CR for 2 or more times; c) The first relapse after chemotherapy and no remission after at least one salvage treatment; c) relapsed after hematopoietic stem cell transplantation; 3. ECOG Scores: 0\~2 4. CD19 positivewere detected by immunohistochemistry or flow cytometry; 5. Estimated survival time\>3 months; 6. Peripheral blood mononuclear immune cells must be collected at least 2 weeks after the last radiotherapy or systemic treatment. Exclusion Criteria: 1. Serious cardiac insufficiency； 2. Has a history of severe pulmonary function damaging; 3. With other tumors which is/are in advanced malignant and has/have systemic metastasis; 4. Severe or persistent infection that cannot be effectively controlled； 5. Merging severe autoimmune diseases or immunodeficiency disease; 6. Patients with active hepatitis B or hepatitis C(\[HBVDNA+\]or \[HCVRNA+\]); 7. Patients with HIV infection or syphilis infection; 8. Has a history of serious allergies on Biological products (including antibiotics); 9. Being pregnant and lactating or having pregnancy within 12 months; 10. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.